SNY's Dupixent is expanding into new diseases and geographies, strengthening its position as a key driver of long-term revenue growth.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

BOCA RATON, FL, UNITED STATES, June 16, 2026 /EINPresswire.com/ -- Baker Legal Team today announced the launch of ...

Sanofi recently raised Dupixent’s peak sales target to more than 13 billion euros and looks to add at least 1.5 million additional eligible patients worldwide by 2025. (Sanofi) Five years after its ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, ...

For the second consecutive month, Dupixent finished as the leader among the top 10 Rx and over-the-counter brands. The eczema and asthma drug from Sanofi and Regeneron had an impressions share of ...

Dupixent is back in the driver’s seat, reclaiming the top spot for ad impressions among Rx and over-the-counter (OTC) brands in May. The eczema and asthma drug from Sanofi and Regeneron had an ...

Dupixent (dupilumab), a drug already used to treat atopic dermatitis and asthma, became the first biologic approved for chronic obstructive pulmonary disease (COPD) last fall. Most COPD treatments ...

Sanofi and Regeneron, whose Dupixent is slated to reach peak sales of at least $4 billion, have continued pumping out new data ion the hope of getting it there sooner rather than later. And today’s ...